Saturday, September 28, 2013

Stem Cell Transplant

Very few of the things we do to treat patients with lymphoma or CLL are more foreign than “transplant.”  When I bring it up as a treatment option, I often get more of a bland reaction than anything else. When it comes to transplant, I suspect the reason is that most patients don’t even know what they don’t know.

It is easy to be scared of the “boogey man” because we all grow up terrified of the mythical character – but transplant?  Few patients have had firsthand experience to understand what it means until they start down that path on their own. Furthermore, there is more misinformation and even fraud out there about “stem cells” than just about any other treatment available.  Even the entire medical community was duped by fraudulent science for a number of years.  Like many aspects of cancer care, an informed patient with good judgment will always be better off.

There are two main types of transplant – autologous (aka. auto – from yourself) and allogeneic (aka. allo – from someone else).

 Auto transplant is really the easiest to understand.  The best way to conceptualize an auto transplant is just “high dose chemotherapy.”  In an auto transplant, the patient donates his own stem cells (normally by a process called apheresis which is a lot like dialysis).  The cells get stored in the freezer for later use. The patient then goes into the hospital for a very high dose of chemotherapy that is enough to wipe out the bone marrow completely.  The doc thaws out the stem cells from the freezer, and infuses them into the patient (via the arm) a day or two later. 

The stem cells magically find their way back to the bone marrow where they set up shop and begin producing new cells.  About three weeks later those stem cells “engraft” and the blood counts start coming back.  It has the effect of exposing the cancer to a very high dose of chemotherapy while protecting the bone marrow by keeping it out of the fight.

During the period of time following the chemotherapy and before engraftment, the patient is pretty fragile medically.  Red blood cell and platelet transfusions are almost always necessary.  Since transfusing white blood cells doesn’t work that well and could even be dangerous the patient is at risk for infections. 

Fevers are the norm as gut bacteria take advantage of the absence of an immune system.  Infections that would often be quite unusual including fungal infections of the sinuses and lungs can become very dangerous.  Just about every patient will be on some powerful antibiotics to get them through those several weeks whether they are treating an infection or trying to prevent one.  The patient is often in the hospital for a considerable part of the time while their immune system is compromised.  A number of transplant centers are able to get the patient out of the hospital for some of the time but getting readmitted is quite common.

Much of the acute risk abates after the first 30 days, but for a nearly a year, there may be some dysfunction of the immune system.  Shingles infections and a weird pneumonia known as PCP (or whatever they have changed its name to this year) can happen during this longer period so preventative antibiotics are fairly common and work pretty well.  Overall, I would say that patients feel like a survivor who has regained their footing somewhere between 30-60 days but the lingering, vague, sense of wellbeing takes quite a bit longer.  I’ve heard patients say they didn’t feel back to “normal” for anywhere between 6-12 months.

Age makes a huge difference for patients going through this.  We always make a point of saying, “chronology does not equal physiology” but as individuals get older the process becomes much harder.  The balance between risk and benefits shifts for the worse somewhere between ages 65-75.  Many 65 year olds could get through this though they will definitely feel quite a bit older when they are done with it.  Other 65 year olds who have acquired lung, heart, or kidney disease along the way may not be eligible.  At the other end, few 75 year olds would be able to get through this.  Many transplant centers will have an age cutoff of around 70 years and may make exceptions for the 72 year old who still does recreational distance running.  Europe tends to be more conservative and age restrictions are more firmly set and may be as young as 60-65 in some cases.

Auto transplant is often employed for patients with Diffuse Large B Cell Lymphoma whose disease has reoccurred after initial therapy.  It is also commonly used in T cell NHL (sometimes in first remission, sometimes after relapse depending on the type and other variables).  It is less frequently used in Follicular Lymphoma (or other indolent NHL’s) for a variety of reasons and rarely (if ever) used in CLL.  Multiple Myeloma is one other blood cancer where it is quite common but I have not written extensively on this blog about that disease.

Allo transplants are an entirely different animal and need considerably more explanation.  The fundamental difference in an allo transplant is that the bulk of the anti-cancer activity comes from the transplanted immune system identifying the cancer and eliminating it.  The hope is that the immune system doesn’t also eliminate the patient at the same time.  Unfortunately it can be hard to control the outcome once the wheels are set in motion.

In allo transplant, there are two main questions.  The first is whether the process will be myeloablative (ie. use powerful chemotherapy to wipe out the bone marrow first) or non-myeloablative (just weaken the immune system enough to slip somebody else’s immune system in).  The second question is how well matched the donor is.  A donor can be a “matched related donor” (MRD), a “matched unrelated donor” (MUD), or a “mismatched unrelated donor.”  There are other significant questions (ie. tumor purging, T-cell depletion, half-match donors (ie. haplo) but I want to finish this post before my plane lands in three hours.

In a myeloablative transplant you pretty much start out with an auto transplant in terms of chemotherapy.  The most obvious difference though is that the stem cells don’t come from the patient – instead they come from somebody else.  In a non-myeloablative transplant you utilize drugs that profoundly weaken the immune system (without getting rid of it completely) enough so that it doesn’t quickly “reject” a bunch of new stem cells as though they were an invading hoard of bacteria.  Interestingly, the drugs utilized  may include campath and fludarabine (two drugs often used to treat CLL in the first place).

The type of donor also makes an enormous difference.  I need to go into a little depth about how the immune system works.  HLA genes are central to how an individual’s immune system interacts with the body and any infections.  When an infection gets into the body, the virus or bacteria gets swallowed by certain cells and chopped up into lots of tiny bits.  These bits then get loaded onto proteins on the surface of the cell encoded by HLA genes sort of like an ice cube in a cup.  This is a process known as “antigen presentation.”  How the little pieces of chopped up virus or bacteria (the ice) sit inthe HLA proteins (the cup) plays an enormous role in whether the immune system decides there is a problem or not.  The better your cup matches somebody else’s cup, the more likely the ice is going to fit the same way (this analogy would work a lot better if it was a really small cup or a really big ice cube so that it was a pretty snug fit)

The major HLA genes are on chromosome 6 and you have two different sets (one from mom and one from dad).  On each chromosome, there are three main sites (HLA-A, HLA-B, and HLA-DR) and each site could have quite a few possible variations (59, 118, 124 respectively).  So there are six different sites that need to match up perfectly and each site could have a multitude of different variations. Therefore there is a very small chance that two genetically unrelated individuals would be a perfect match.   Since half of your HLA genes come from mom and half from dad and in each case they are inherited in unison (ie you get one chromosome with three automatic matches), you have a one in four chance of matching a biologic sibling. 

By definition, you could NOT be a match with either a parent or a child (half match at best unless they were cloned).  I did have a memorable patient from an area where individuals were occasionally known to get married to a relative.  He told me, “Son, my family tree don’t branch.”  You should  know that donor searches sometimes turn up family surprises (albeit rarely).

Beyond the “major” HLA genes, there are a bunch of “minor” genes that are so numerous and so variable, that it is simply best if you have a sibling donor that is a match.  That will almost always be the best fit.  If you didn’t win the sibling lottery with the 1/4 chance of a match, then they look through the donor registries.  I’ve never understood why this can take so long – but it does.  North American Caucasians have a pretty darn good chance of finding several matches.  Once you start throwing in ethnic minorities into the gene pool though, the chance of finding a match gets lower (not impossible).  Often they may find multiple donors that match and then they can utilize additional techniques to figure out who is a “better match.”  Sometimes banked umbilical cord blood can serve as the donor tissue in certain centers. 

Once a match is found, and the “conditioning regimen” is given to the patient (whether that is myeloablative chemotherapy, or non-myeloablative therapy), the new stem cells are injected.  These can take a while to engraft just like in auto transplants above.

Once the cells are engrafted, a new challenge arises.  Since these immune system is from another person, it will start to attack the body it was put into in a process called “graft versus host disease” (aka. GVHD).  The physician therefore needs to “lower” the new immune system by giving drugs like methotrexate and cyclosporine.  These are not necessarily easy drugs to manage.

You might therefore ask, “if I am getting a new immune system to attack my cancer, why are you choosing to handicap it?”  GVHD can be a lot worse than the cancer at times.  GVHD is divided into early versus late depending on which side of 100 days it falls.  Acute GVHD can manifest with dangerous rash, diarrhea, and liver dysfunction.  Chronic GVHD can have just about any sort of problem you can imagine, but often includes skin and gastrointestinal side effects.  Acute GVHD can be life threatening if not managed correctly.  Simultaneously with a lowered immune system, infections can be an enormous problem.

The danger often subsides with time and the immune suppression can be lowered.  This enables the transplanted immune system to go after the cancer.  Since that can take a while though, it makes most sense for patients to have their disease under optimal control before going into transplant.  If you have a lot of CLL running around, chances are it will progress before the immune system can go after it.  Furthermore, the immune system may think the cancer is supposed to be there, then you are stuck with both the cancer and the GVHD…..aargh.

If everything goes well, the transplant center may let you return to your home community after about 100 days.  Yes – you may need to temporarily live near the hospital for several months.  Transplant programs often have arrangements to make this possible. 

If all goes well, you may indeed be cured of your disease.  For something like relapsed DLBCL or CLL, that can be a life you would not possible have any other way.  It makes it quite a high stakes gamble.  There is both high risk and potentially high reward.

Many have heard about the new “engineered T-cells.”  I am on my way back from the IWCLL meeting (international workshop on CLL) where we heard an update on this technology.  Looks like 1 out of four patients may be genuinely cured by this.  Another 1 out of 4 get a partial response.  For half of those it is brief and the other half it continues to improve over time.  2 out of 4 patients may not benefit from the procedure.

These are impressive statistics for a procedure that functions like an “allo transplant” but by definition does not have the risk of GVHD.  Numbers are still VERY small.  Something like 30 patients have been treated at Penn TOTAL.  I think in the long run, this will be done before allo transplants – but it is still early enough that it remains difficult to predict.

Hopefully that is a good orientation.  It is by no means complete but I think I’ve officially got a writers cramp. 

Thanks for reading

Monday, September 23, 2013

Summer off

I started this blog about a year ago by writing about the molecular biology of B cell cancers figuring there may be an audience wanting to understand more about CLL and NHL but unable to find the type of material they wanted.  There are lots of physicians who write to physicians, and medical writers who write to patients, but not as many doctors who write to patients.  Furthermore, in cases where doctors do write for patients, such articles are often watered down for the “average” individual.  I’m sure I occasionally get too technical with my writings, but I like to aim high and it seems that appeals to those of you who have faithfully followed my posts.  Thank you to those who continue to read even though it may at times include challenging language and terminology.

I’ve largely taken the summer off from writing.  Creating content for the blog can take quite a bit of time.  With the unbelievable multitude of new drugs to be studied in CLL/NHL, my life has been filled with protocol reviews, cancer conferences, and local research management issues - on top of an extremely busy clinic.
I guess one lesson of my job is that you can’t take a pass on living life when you have the chance.  Summer in Oregon is magical.  There are few places as beautiful as the Pacific Northwest this time of year.  There are few joys equal to taking the family for a hike and swimming in waterfalls.
But the seasons change. 
While I am not yet ready to let go of summer, school has started, the Oregon Ducks football team is playing again, and the research meeting schedule is already in full swing.  The rain has started early this year.  Soon the leaves will be changing and the “indoor season” will be upon us.

I will probably start writing a little more again as the days get shorter and going out to feel the warmth of the summer sun is no longer an option.  I’m not sure I will hit the productivity I did last spring when the post ideas just kept coming to me, but hopefully I can keep updating this with things you might find interesting.  I've got a few video posts ready to go, and a deep dive on 11q- mostly done.

I hope you have all had a good summer too.  Many readers of this blog are here because of some unwanted realities.  I hope that in the midst of your journeys, you can pause and find the things around you that are indeed good.  Cancer is a weird journey.  I’ve heard many patients comment that it has provided them with clarity to life that enables them to focus on what is really important. 

In that way, I hope I can learn from you all too.  Thank you for teaching me what is really important in life.  I just wish I was a better student of the lessons you all hold.  My waterfall hike this summer was a brief moment in time but it will be an everlasting memory.

Thank you.

Wednesday, September 11, 2013

Video update from IWCLL

I had the chance to meet up with Andrew Schorr in Germany at the IWCLL meeting. We taped this interview to provide an overview of where the new CLL drugs may best fit into an individuals treatment plan.  Hopefully it is a good summary for you and puts things into a more focused perspective.

Andrew does a great job collecting the voices of many experts and putting them into one place. If you haven't made a contribution to his efforts, you might want to think about doing so. We are lucky to have him out on the front lines.

I apologize for being a little long winded in response to his questions.  So much exciting stuff to talk about, I had a hard time containing myself.